Global Rheumatic Disorders Drugs Market Grow at (CAGR) of 4.46% to $80.04 billion in 2024

Global Rheumatic Disorders Drugs Market to 2024 research report covers key diseases of rheumatic disorders, market size, therapy area overview, etiology, Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation and key marketed products.

Pune, India - February 12, 2019 /MarketersMedia/ —

Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry research report added to ReportsnReports online database.
The rheumatic disorder therapy area is multi-disciplinary in nature and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion. The majority of rheumatic disorders are treated using largely genericized pain management drugs, and there are no cures for any of the key indications, leaving a large unmet need for better disease-modifying drugs to be developed.

Get Discount on Rheumatic Disorders Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854866

This report covers all rheumatic disorders, but there is a particular focus on five key diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus and psoriatic arthritis, as these conditions have the largest pipelines within the therapy area.

The market size for rheumatic disorder therapeutics was $58.97 billion in 2017 and is expected to grow at a compound annual growth rate (CAGR) of 4.46% to $80.04 billion in 2024.

Scope

- How is the rheumatic disorders market landscape expected to change?
- Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period?
- Overall, there are 1,069 products in the rheumatic disorder pipeline, how does the composition of the pipeline compare with that of the existing market?
- Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition?
- The market size for rheumatic disorder therapeutics is expected to grow, from $58.97 billion in 2017 to $80.04 billion in 2024, at a CAGR of 4.46%. Which products will contribute to market growth most, and which will achieve blockbuster status?
- What types of companies are involved in the rheumatic disorder therapy area?
- Will the current market leaders retain their dominance over the forecast period?
- How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values?

Reasons to Buy:
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the five key indications
- Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the Rheumatic Disorder Drug Market
- Identify trends and developments in the rheumatic disorder pipeline and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates
- Identify which two drug classes will see particularly strong market growth over the forecast period
- See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion
- Identify commercial opportunities in the rheumatic disorder deal landscape by analyzing trends in licensing and co-development deals

Direct Purchase of Rheumatic Disorders Drugs Market Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854866

Table of Contents:
1. Introduction
2. Key Marketed Products
3. Pipeline Landscape Assessment
4. Multi-scenario Market Forecast to 2024
5. Company Analysis and Positioning
6. Strategic Consolidations
7. Appendix

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854866-global-rheumatic-disorders-drugs-market-to-2024-increased-uptake-of-il-inhibitors-and-jak-inhibitors-to-drive-growth-as-tnf-inhibitors-face-patent-expiry.html

Source URL: https://marketersmedia.com/global-rheumatic-disorders-drugs-market-grow-at-cagr-of-446-to-8004-billion-in-2024/481750

Source: MarketersMedia

Release ID: 481750

Latest News

Orangutan mother blinded by air gun pellets in Indonesia

Mar 20, 2019

SIBOLANGIT, Indonesia — An orangutan mother has been blinded after being shot with at least 74 air gun pellets on Indonesia's Sumatra island, where threats to the endangered species have increased as the palm oil and paper industries shrink its jungle habitat. An X-ray showed at least 74 air gun pellets in her body, including four in her left eye and two in the right, said veterinarian Yenny Saraswati with the Sumatran Orangutan Conservation Program. The great ape, named "Hope" by her rescuers, also had several wounds believed to have been caused by sharp objects, she said Monday. Hope also...

Jakarta's 1st subway to ease frustration, sweat and fumes

Mar 20, 2019

JAKARTA, Indonesia — Commuting in Indonesia's gridlocked capital will for some involve less frustration, sweat and fumes when its first subway line opens later this month. The line is the latest of infrastructure improvements nationwide that officials hope will help the giant but laggard nation catch up with its neighbors. The 16-kilometer (10-mile) system running south from Jakarta's downtown is the first phase of a development that if fully realized will plant a cross-shaped network of stations on the teeming city of 30 million people. A $2.4 billion elevated rail network linking Jakarta and its satellite cities is also taking...

Asian stocks edge up on stimulus hopes after Chinese data

Mar 20, 2019

SINGAPORE — Asian markets were mostly higher Thursday as slowing Chinese industrial output left traders hopeful of more assurances from Beijing. Japan's benchmark Nikkei 225 gained 0.7 percent to 21,431.28 and the Kospi in South Korea was up 0.1 percent at 2,149.48. Hong Kong's Hang Seng added 0.1 percent to 28,840.30. Australia's S&P/ASX 200 rose 0.1 percent to 6,167.00. The Shanghai Composite lost 0.6 percent to 3,010.06. Shares were flat in Taiwan but fell in Singapore and the Philippines. China's industrial output grew 5.3 percent in the first two months of 2019 from the same period last year, official data...

Malaysia shuts 111 schools as toxic waste sickens students

Mar 20, 2019

KUALA LUMPUR, Malaysia — Toxic waste illegally dumped into a river in southern Johor state sickened scores of students and teachers, prompting Malaysia's government to order 111 schools to close Wednesday. Education Minister Maszlee Malek earlier Wednesday told 34 schools to shut down and later said that number was up to 111 schools. He didn't give details. More than 500 people were treated for breathing difficulties, dizziness, nausea and vomiting after inhaling toxic fumes from the waste. Officials said 166 people were hospitalized, and several were under intensive care. Environment Minister Yeo Bee Yin was quoted by the country's Bernama...

Indonesia, experts wary of linking Boeing crashes

Mar 20, 2019

JAKARTA, Indonesia — Two fatal crashes of Boeing 737 Max 8 planes less than five months apart have raised alarm, but experts are wary of linking the two. The head of Indonesia's National Transportation Safety Committee, Soerjanto Tjahjono, said Tuesday it was unclear if the cause of Sunday's disaster in Ethiopia was similar to the still-undetermined reason for a Lion Air crash in October. Tjahjono said his agency is waiting for Ethiopian authorities to respond to its offer to assist with the investigation into the crash that killed all 157 people aboard. The Max 8 operated by Indonesia's Lion Air...